The frequency and availability of population-specific patient reported outcome measures and minimal clinically important differences among approved drugs in Canada

BACKGROUND: Patient reported outcome measures (PROMs) and minimal clinically important differences (MCIDs) are included in Canada’s Common Drug Review (CDR) process to approve new drugs. Often, the measures report on the health-related quality of life (HRQoL), but can also describe the symptoms, eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Soprovich, Allison, Ingstrup, Meghan, Eurich, Dean T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322322/
https://www.ncbi.nlm.nih.gov/pubmed/30616654
http://dx.doi.org/10.1186/s12955-018-1070-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6322322/
https://www.ncbi.nlm.nih.gov/pubmed/30616654
http://dx.doi.org/10.1186/s12955-018-1070-0

Ejemplares similares